RAB19

Across TCGA pan-cancer cohorts, RAB19 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RAB19 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RAB19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB19 expression acts as an unfavorable survival marker.

BRCA and PRAD are the cancer types where RAB19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.125	0.578	.005	16	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RAB19–BRCA (OS)

Open the BRCA breakdown →